Abstract
The fundamental goal of maintenance therapy of cancer is to extend a clinically meaningful survival endpoint (overall, symptom-free, progression-free) while at the same time not substantially interfering with a patient’s quality of life. Several phase 3 randomized trials in ovarian cancer involving different anti-neoplastics (e.g., paclitaxel, anti-angiogenic agents, olaparib) have revealed an improvement in progression-free survival with generally acceptable side effect profiles, and as a result represent in appropriately selected patients a rational therapeutic strategy.
Similar content being viewed by others
References
Maughan, T. S., James, R. D., Kerr, D. J., et al. (2003). Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomized trial. Lancet, 361, 457–464.
Owonikoko, T. K., Ramalingam, S. S., & Belani, C. P. (2010). Maintenance therapy for advanced non-small cell lung cancer: current status, controversies, and emerging consensus. Clinical Cancer Research, 11, 521–529.
Muss, H. B., Case, L. D., Richards, F., et al. (1991). Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. New England Journal of Medicine, 325, 1342–1348.
Katz, M. E., Schwartz, P. E., Kapp, D. S., et al. (1981). Epithelial carcinoma of the ovary: current strategies. Annals of Internal Medicine, 95, 98–111.
Young, P. C., Chabner, B. A., Hubbard, S. P., et al. (1978). Advanced ovarian adenocarcinoma: a prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. New England Journal of Medicine, 299, 1261–1266.
Greene, M. H., Boice, J. D., Jr., Greer, B. E., et al. (1982). Acute nonlymphocytic leukemia after therapy with alkylating agents for ovarian cancer: a study of five randomized trials. New England Journal of Medicine, 307, 1416–1421.
Travis, L. B., Curtin, R. E., Boice, J. D., Jr., et al. (1996). Second malignant neoplasms among long-term survivors of ovarian cancer. Cancer Research, 56, 1564–1570.
Lambert, H. E., Rustin, G. J., Gregory, W. M., et al. (1997). A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma. A North Thames Ovary Group Study. Annals of Oncology, 8, 327–333.
Bertelsen, K., Jakobsen, A., Stroyer, J., et al. (1993). A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Gynecologic Oncology, 49, 30–36.
Hakes, T. B., Chalas, E., Hoskins, W. J., et al. (1992). Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecologic Oncology, 45, 284–289.
Rowinsky, E. K., & Donohower, R. C. (1995). Paclitaxel (taxol). New England Journal of Medicine, 332, 1004–1014.
McGuire, W. P., Rowinsky, E. K., Rosenshein, N. B., et al. (1989). Taxol: a unique anti-neoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Annals of Internal Medicine, 111, 273–279.
Thigpen, J. T., Blessing, J. A., Ball, H., et al. (1994). Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. Journal of Clinical Oncology, 12, 1748–1753.
Miller, K. D., Sweeney, C. J., & Sledge, G. W., Jr. (2001). Redefining the target: chemotherapeutics as antiangiogenics. Journal of Clinical Oncology, 19, 796–799.
Markman, H., Hakes, T., Barakat, R., et al. (1996). Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer. Journal of Clinical Oncology, 14, 796–799.
Rohl, J., Kushner, D., & Markman, M. (2001). Chronic administration of single-agent paclitaxel in gynecologic malignancies. Gynecologic Oncology, 81, 201–205.
Von Gruenigen, V., Karlen, J. R., & Waggoner, S. E. (2003). A case of chronic paclitaxel administration in ovarian cancer. Gynecologic Oncology, 89, 532–535.
Markman, M., Liu, P. Y., Wilczynski, S., et al. (2003). Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group trial. Journal of Clinical Oncology, 21, 2460–2465.
Markman, M., Liu, P., Wilcyznski, S., et al. (2009). Impact on survival of 12 versus 3 monthly cycles of paclitaxel (175 mg/m2) administered to patients with advanced ovarian cancer who attained a complete response to primary platinum-paclitaxel: follow-up of a Southwest Oncology Group and Gynecologic Oncology Group phase 3 trial. Gynecologic Oncology, 114, 195–198.
Broglio, K. R., & Berry, D. A. (2009). Detecting an overall survival benefit that is derived from progression-free survival. Journal of the National Cancer Institute, 101, 1642–1649.
Pecorelli, S., Favalli, G., Gadducci, A., et al. (2009). Phase III trial of observation versus six courses of paclitaxel in patients with advanced epithelial ovarian cancer in complete response after six courses of paclitaxel/platinum-based chemotherapy: final results of the After-6 Protocol 1. Journal of Clinical Oncology, 27, 4642–4648.
Del Placido, S., Scambia, G., Di, V. G., et al. (2004). Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian Trials in Ovarian Cancer (MITO-1) randomized study. Journal of Clinical Oncology, 22, 2635–2642.
Pfisterer, J., Weber, B., Reuss, A., et al. (2006). Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a Gynecologic Intergroup trial of the AGO-AOVAR and GINECO. Journal of the National Cancer Institute, 98, 1036–1045.
Bolis, G., Danese, S., Tateo, S., et al. (2006). Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study. International Journal of Gynecological Cancer, 16(suppl 1), 74–78.
Alberts, D. S., Jiang, C., Liu, P. Y., et al. (2004). Long-term follow-up of a phase II trial of oral altretamine for consolidation of complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology Group. International Journal of Gynecological Cancer, 14, 224–228.
Ferrara, N., & Kerbel, R. S. (2005). Angiogenesis as a therapeutic target. Nature, 438, 967–974.
Burger, R. A., Sill, M., Monk, B. J., et al. (2007). Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. Journal of Clinical Oncology, 25, 5165–5171.
Cannistra, S. A., Matulonis, U. A., Person, R. T., et al. (2007). Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer. Journal of Clinical Oncology, 25, 5180–5186.
Burger, R. A., Brady, M. F., Bookman, M. A., et al. (2011). Incorporation of bevacizumab in the primary treatment of ovarian cancer. New England Journal of Medicine, 365, 2473–2483.
Perren, T. J., Swart, A. M., Pfisterer, J., et al. (2011). A phase 3 trial of bevacizumab in ovarian cancer. New England Journal of Medicine, 365, 2484–2496.
Aghajanian, C., Blank, S. V., Goff, B. A., et al. (2012). OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. Journal of Clinical Oncology, 30, 2039–2045.
Pujade-Lauraine, E., Hilpert, F., Weber, B., et al. (2012). AURELIA: a randomized phase III trial evaluating bevacizumab plus chemotherapy for platinum-resistant ovarian cancer. Journal of Clinical Oncology, 30 (suppl; LBA 5002).
Burger, R. A. (2011). Overview of anti-angiogenic agents in development for ovarian cancer. 121:230–238.
De Bois, A., Floquet, A., Kim, J. W., et al. (2013). Randomized, double-blind, phase III trial of pazopanib versus placebo in women who have progressed after first-line chemotherapy for advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer: results of an international Intergroup trial (AGO-OVAR 16). Journal of Clinical Oncology, 31(suppl; LBA 5503).
Hall, G. D., Brown, J. M., Coleman, R. E., et al. (2004). Maintenance treatment with interferon for advanced ovarian cancer: results of the Northern and Yorkshire Gynecology Group randomized phase III study. British Journal of Cancer, 91, 621–626.
Alberts, D. S., Hannigan, E. V., Liu, P. Y., et al. (2006). Randomized trial of adjuvant intraperitoneal alpha-interferon in stage III ovarian cancer patients who have no evidence of disease after primary surgery and chemotherapy: an intergroup study. Gynecologic Oncology, 100, 133–138.
Berek, J., Taylor, P., McGuire, W., et al. (2009). Oregovomab maintenance monoimmunotherapy does not improve outcomes in advanced ovarian cancer. Journal of Clinical Oncology, 27, 418–425.
Sabbatini, P., Harter, P., Scambia, G., et al. (2013). Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO—The MIMOSA Study. Journal of Clinical Oncology, 31, 1554–1561.
Vergote, I. B., Jimeno, A., Joly, F., et al. (2014). Randomized phase III study of erlotinib versus observation in patients with no evidence of disease progression after first line platinum-based chemotherapy for ovarian carcinoma: a European Organization for Research and Treatment of Cancer—Gynaecological Cancer Group and Gynecologic Cancer Intergroup study. Journal of Clinical Oncology, 32, 320–326.
Schilder, R. J., Sill, M. W., Chen, X., et al. (2005). Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group study. 11:5539–5548.
Fong, P. C., Yap, T. A., Boss, D. S., et al. (2010). Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. Journal of Clinical Oncology, 28, 2512–2519.
Ledermann, J., Harter, P., Gourley, C., et al. (2012). Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. New England Journal of Medicine, 366, 1382–1392.
Farmer, H., McCabe, N., Lord, C. J., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434, 917–921.
Hennessy, B. T. J., Timms, K., Carey, M. S., et al. (2010). Somatic mutations in BRCA1 and BRCA2 could expand the number of patients that benefit from PARP inhibitors in ovarian cancer. Journal of Clinical Oncology, 28, 3570–3576.
Ledermann, J. A., Harter, P., Gourley, C., et al. (2013). Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer and a BRCA mutation. Journal of Clinical Oncology, 31(suppl; Abstract 5505).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Markman, M. Maintenance chemotherapy in the management of epithelial ovarian cancer. Cancer Metastasis Rev 34, 11–17 (2015). https://doi.org/10.1007/s10555-014-9537-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10555-014-9537-x